54624-58-7

Upstream product

• 51-17-2 benzoimidazole 
• 3587-60-8 Benzyloxymethyl chloride 
• 50-00-0 formaldehyd 
• 95-54-5 1,2-diamino-benzene 
• 100-51-6 benzyl alcohol 

Downstream Products

• 328927-46-4 1-{5-[(1H-benzoimidazol-2-yl)-hydroxy-methyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-(tert-butyl-diphenyl-silanyloxy)-ethanol 
• 328927-48-6 2-[5'-O-(tert-butyldiphenylsilyl)-2',3'-O-isopropylidene-β-D-ribofuranosyl-1']benzimidazole 

Relevant academic research and scientific papers

Nano indium oxide-catalyzed domino reaction for the synthesis of N-alkoxylated benzimidazoles

A convenient method has been developed for the selective synthesis of N-alkoxylated benzimidazole derivatives by the cyclocondensation reaction of simple ortho-phenylenediamine, formaldehyde and alcohols in presence of indium oxide nanoparticles as catalyst. The alcohol acts as reactant as well as solvent in this reaction. No other solvents or additives have been used for this reaction. The catalyst can be reused several times without significant loss of catalytic activity. A probable reaction mechanism has been proposed based on some control experiments.

C2-Selective Branched Alkylation of Benzimidazoles by Rhodium(I)-Catalyzed C-H Activation

Herein, we report a Rh(I)/bisphosphine/K3PO4 catalytic system allowing for the first time the selective branched C-H alkylation of benzimidazoles with Michael acceptors. Branched alkylation with N,N-dimethyl acrylamide was successfully applied to the alkylation of a broad range of benzimidazoles incorporating a variety of N-substituents and with both electron-rich and -poor functionality displayed at different sites of the arene. Moreover, the introduction of a quaternary carbon was achieved by alkylation with ethyl methacrylate. The method was also shown to be applicable to the C2-selective branched alkylation of azabenzimidazoles.

Heterocyclic compounds as inhibitors of factor VIIa

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

THIENOPYRAZOLES

Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).

Stereocontrolled synthesis of heterocyclic C-nucleosides. Protecting group effect and molecular modeling studies.

We report herein a short stereocontrolled synthesis of heterocyclic C-nucleosides (indole, imidazole, benzimidazole, and 6-iodobenzimidazole). First, condensation of 2-lithiated heterocycles 2-5 with 5-(tert-butyldiphenylsilyl)-2,3-O-isopropylidene-D-gamma-ribonolactone (1) afforded the hemiacetals 6-9 in good yields. Then, borohydride reduction (NaBH(4)) of the protected hemiacetals proceeded stereoselectively to give predominantly the S diols 10-13, which upon Mitsunobu cyclization afforded the alpha-C-nucleosides 14-17. In contrast, the same PPh(3)/DEAD treatment of the 1:1 diastereomeric mixture of the free heterocyclic diols 10d and 11d gave exclusively the beta-anomers 14dbeta and 15dbeta, respectively, by a stereocontrolled process. The mechanisms of these stereocontrolled steps are discussed with the support of molecular modeling studies.